ARS Pharmaceuticals (SPRY) Income from Continuing Operations (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Income from Continuing Operations of 95931000.0 for Q1 2026, down 120.44% sequentially from 43518000.0 in Q4 2025, and down 156.94% YoY from 168478282.89 in Q1 2025.
Powered by 
Analysis
ARS Pharmaceuticals (SPRY) Income from Continuing Operations (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Income from Continuing Operations for 7 years, with the latest figure at 95931000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 156.94% year-over-year to 95931000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 474699000.0 (down 122.98% YoY) and the FY2025 annual result came in at 171298000.0, down 2241.76% from the prior year.
- Income from Continuing Operations declined to 95931000.0 in Q1 2026 per SPRY's latest filing, from 43518000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 47262000.0 in Q4 2024 and troughed at 39407246000.0 in Q1 2023.
- A 5-year average of 5524265176.47 and a median of 67407000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations plunged 339646.93% in 2023, then jumped 571.87% in 2024.
- Over 5 years, Income from Continuing Operations stood at 15136000.0 in 2022, then jumped by 33.83% to 10016000.0 in 2023, then surged by 571.87% to 47262000.0 in 2024, then sank by 192.08% to 43518000.0 in 2025, then tumbled by 120.44% to 95931000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 95931000.0, 43518000.0, and 112977000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 10 | ARS Pharmaceuticals | 564.59 Mn | 420.75 Mn | 20.81 Mn | -63.99 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -63.99 Mn |
| Mar 31, 2026 | -62.81 Mn |
| Dec 31, 2025 | -41.33 Mn |
| Sep 30, 2025 | -53.15 Mn |
| Jun 30, 2025 | -47.73 Mn |
| Mar 31, 2025 | -37.33 Mn |
| Dec 31, 2024 | 47.08 Mn |
| Sep 30, 2024 | -21.26 Mn |
| Jun 30, 2024 | -15.36 Mn |
| Mar 31, 2024 | -13.37 Mn |
| Dec 31, 2023 | -10.02 Mn |
| Sep 30, 2023 | -17.96 Mn |
| Jun 30, 2023 | -20.85 Mn |
| Mar 31, 2023 | -19.05 Mn |
| Dec 31, 2022 | -15.04 Mn |
| Sep 30, 2022 | -6.63 Mn |
| Jun 30, 2022 | -6.34 Mn |
| Mar 31, 2022 | -7.10 Mn |
| Dec 31, 2021 | 46.66 Mn |
| Sep 30, 2021 | -22.72 Mn |